that is not true in my opinion. a partner can offe

that is not true in my opinion. a partner can offer cash and better influence over the FDA. there are many BP in this position. Cytodyn is offering a drug that know one else has and will not be able to have. There are many potential partners, there is only one cytodyn and only one Leronlimab. Before you say leronlimab has no value until it is approved, it has value in the fact that one partner will have access to leronlimab and all others will not. that is very valuable as opportunity lost for all others.

Last we all checked, Cytodyn is not folding up shop and they have not stated than there are no more NDA's because no deals were and will ever be made.